Fundraising FoxDNA Lite
San Francisco, US · 3 known investors
Find your way into DNA Lite
Sign up to see every warm intro you have to DNA Lite
- Paths you didn't know you had: your email and LinkedIn already hold routes to the DNA Lite team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.
Founders & leadership
MA
Mubhij AhmadNamed on SEC filing
DR
David RabukaNamed on SEC filing
TP
Timothy Paul DayNamed on SEC filing
Board
Investors · 3
Berkeley Catalystlisted by Berkeley CatalystBerkeley
How we know: the VCSheet dataset · Not right? Tell us
Blue Bear Ventureslisted by Blue Bear VenturesBerkeley · $100K – $400K
How we know: Blue Bear Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.6M disclosed across 1 round · 2022
▶$5.6MraisedApr 2022 · 18 investors · BiotechnologyRule 506(b)
▶$5.6MraisedApr 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mubhij AhmadExecutive Officer, Director
- David RabukaDirector
- Timothy Paul DayDirector
- Andrew Cain McClaryDirector
- Drew LanzaDirector
- Offering amount
- $8.9M
- Amount sold
- $5.6M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does DNA Lite do?
- Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company developing an oral lipid nanoparticle platform to deliver nucleic acids, such as mRNA, to the intestinal epithelium. It focuses on oral mRNA medicines.
- Who are DNA Lite's investors?
- DNA Lite's investors include Berkeley Catalyst, Blue Bear Ventures, KdT Ventures.
- How much funding has DNA Lite raised?
- DNA Lite has disclosed $5.6M raised across 1 round.
- Where is DNA Lite headquartered?
- DNA Lite is headquartered in San Francisco, US.